Shares of Rezolute Inc. (RZLT) touched a new 52-week high of $8.06 last week amid FDA alignment on a significantly streamlined clinical development path for its lead asset, Ersodetug, in tumor-induced hyperinsulinism, as well as growing anticipation ahead of an upcoming trial catalyst in congenital hyperinsulinism.
Ersodetug is a fully human monoclonal antibody designed to help control blood sugar levels. It works in a unique way by attaching to insulin receptors in the body to reduce the effects of too much insulin or related hormones. It is administered by IV infusion every 2 to 4 weeks.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com